Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.65 |
| ▸ | CTSS | P25774 | 4/20 | 0.61 |
| ▸ | PPARG | P37231 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KLK7 | P49862 | 2/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212796 | 1.00 | PPARA (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL1132570 | 1.00 | PPARA (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL18407225 | 0.93 | PPARA (0.69) | PPARACTSSPPARGATMSYK | |
| SCHEMBL31266138 | 0.90 | PPARA (0.62) | PPARACTSSPPARGATMSYK | |
| SCHEMBL31048314 | 0.90 | PPARA (0.62) | PPARACTSSPPARGATMSYK | |
| SCHEMBL25467757 | 0.90 | PPARA (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL27538401 | 0.90 | ATM (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL903406 | 0.90 | ATM (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL397123 | 0.88 | PPARA (0.63) | PPARACTSSPPARGATMSYK | |
| SCHEMBL740897 | 0.88 | PPARA (0.63) | PPARACTSSPPARGATMSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651951-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651946-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651948-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651953-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651947-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651945-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4592296-A1 | NOVEL TETRAHETEROCYCLE COMPOUND | Idience Co., Ltd. (KR) | 2025-07-30 | — | — | EP | disclosed |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | ARTIOS PHARMA LIMITED (GB) | 2025-07-15 | — | — | US | disclosed |
| US-20250066368-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2025-02-27 | — | — | US | disclosed |
| EP-4455129-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2024-10-30 | — | — | EP | disclosed |
| CN-1244202-A | Tricyclic erythromycin derivatives | ABBOTT LAB (US) | 2000-02-09 | — | — | CN | disclosed |
| EP-0961776-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5969135-A | COMPOUNDS FOR USE AS ANTISENSE CONTROL OF GENE EXPRESSION AND HYBRIDIZATION | ICN PHARMACEUTICALS, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0789707-A4 | AMINO ACID NUCLEIC ACIDS | ICN PHARMACEUTICALS (US) | 1999-02-24 | — | — | EP | disclosed |
| EP-0876388-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1998-11-11 | — | — | EP | disclosed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | disclosed |
| CN-1171112-A | Amino acid nucleic acids | ICN PHARMACEUTICALS CO (US) | 1998-01-21 | — | — | CN | disclosed |
| EP-0789707-A1 | AMINO ACID NUCLEIC ACIDS | ICN PHARMACEUTICALS (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997017356-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-05-15 | — | — | WO | disclosed |
| WO-1996014330-A1 | AMINO ACID NUCLEIC ACIDS | ICNPHARMACEUTICALS (US) | 1996-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066368-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | POLQ, POLB, POLM | PPARA 2214/4885CTSS 3283/4885PPARG 2667/4885 |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | SDHA, DPYD, TP53 | PPARA 483/4885CTSS 1753/4885PPARG 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.